Exploring targeted therapy in retinal vasculopathy with cerebral leukoencephalopathy: a case report and review of
Patricia Tato-Moreno1,2, Cristina Lavilla Olleros2,3, Héctor Balastegui Martín4
1Immunology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Abstract:
Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is a rare autosomal dominant microvascular disorder caused by C-terminal truncating mutations in TREX1 gene, which impair protein localization and lead to multisystem involvement. We report a patient carrying the pathogenic TREX1 variant NM_033629.6:c.703dup (p.Val235fs), the most frequently described mutation in RVCL-S, whose clinical course was consistent with the classic phenotype but with simultaneous pulmonary granulomatous lesions compatible with sarcoidosis. Transcriptomic analysis in both the patient and his pre-asymptomatic daughter, who carries the same variant, revealed a similarly mild upregulation of inflammatory signaling pathways. Treatment with a Janus kinase inhibitor in the patient was followed by transient clinical stabilization before subsequent progression. This case expands the phenotypic spectrum of RVCL-S and underscores the importance of systematic immunological monitoring and clinical surveillance to support future development of timely strategies in asymptomatic carriers.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Data Reporting and Recording
Gene Therapy
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:


